Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study.
about
Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell VaccinesLymphoma Immunotherapy: Current StatusClinical trials of dendritic cell-based cancer vaccines in hematologic malignanciesCurrent translational and clinical practices in hematopoietic cell and gene therapyIn situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II studyThe novel C24D synthetic polypeptide inhibits binding of placenta immunosuppressive ferritin to human T cells and elicits anti-breast cancer immunity in vitro and in vivo.The immune response to tumors as a tool toward immunotherapy.A think tank of TINK/TANKs: tumor-infiltrating/tumor-associated natural killer cells in tumor progression and angiogenesis.Progression of Large Lymphoma Is Significantly Impeded with a Combination of Gemcitabine Chemotherapy and Dendritic Cells Intra-Tumor Vaccination.Haematological malignancies: at the forefront of immunotherapeutic innovation.TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas.Enhancement of dendritic cells as vaccines for cancerUtilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.Therapeutic potential of dendritic cell vaccines in sarcoma of the extremities.The Roles of Radiotherapy and Immunotherapy for the Treatment of LymphomaLymphoma immunotherapy: vaccines, adoptive cell transfer and immunotransplant.Adoptive T-cell therapy for B-cell malignancies.Vaccination strategies in lymphomas and leukaemias: recent progress.Active immunotherapy: current state of the art in vaccine approaches for NHLNK cells: key to success of DC-based cancer vaccines?Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers.A review of dendritic cell therapy for cancer: progress and challenges.Monitoring regulatory immune responses in tumor immunotherapy clinical trials.Exploiting dendritic cells in the development of cancer vaccines.DC-based immunotherapy for hematological malignancies.Natural killer cells as helper cells in dendritic cell cancer vaccines.Minor histocompatibility Ags: identification strategies, clinical results and translational perspectives.In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf.Cellular immunotherapy of cancer: an overview and future directions.In situ vaccination for the treatment of cancer.Challenges in vaccine therapy in hematological malignancies and strategies to overcome them.Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update.Enhanced therapeutic effect of B cell-depleting anti-CD20 antibodies upon combination with in-situ dendritic cell vaccination in advanced lymphoma.Dendritic Cell Therapies for Hematologic Malignancies.Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy.Dendritic cell therapy for oncology roundtable conference.Artificial human antigen-presenting cells are superior to dendritic cells at inducing cytotoxic T-cell responses.Detecting T-cell reactivity to whole cell vaccines: Proof of concept analysis of T-cell response to K562 cell antigens in CML patients.Immunotherapy for B-cell lymphoma: current status and prospective advancesCombining low-dose or metronomic chemotherapy with anticancer vaccines: A therapeutic opportunity for lymphomas.
P2860
Q26772715-F91E3901-D352-452E-B4C8-D8606270EAC5Q26782902-1B13953E-D4AE-497B-875B-3AAB638AD12FQ26864603-19755F3A-B133-4526-BF6C-83B0E5C6FEBBQ27024456-3F9EB574-1BBD-44A1-89D7-C0A08EF4EF45Q34194680-5A6CD3D1-91D7-49A3-9C86-B715834CE676Q34529278-2190902F-DD1E-45BB-8EA0-DF426F369365Q34634545-AFDCD2CF-7E78-4640-923B-6DB39E76D657Q35131244-3F1A06E7-4A7E-4EC4-ADE1-CD75A92B6C55Q35693324-4092143F-5FA8-425B-A909-A13ED585F115Q35880618-DD6C6F87-8417-4C55-9CFE-3795571DDEBAQ36194235-D2DB9AF7-157B-4F2B-81FC-BAA59D7BFC51Q36209210-2E085FAD-1B34-4433-A903-D5A4016CF709Q37058110-E9251242-A628-4C24-A7D8-BC8806542B0DQ37577912-B76ABBC0-D423-4046-B158-C86538B66208Q37640319-E95E07E7-69A7-4F35-BC6C-B78F36CB28C9Q37773301-92021B22-FA33-4189-B5E8-6D8242C4BAA8Q37810116-E6EE6BE3-72A8-4AD0-979D-0C87076BBC32Q37929157-D15B0E27-C9CC-4660-B636-C16BF91F1195Q38030484-5F3DD9E2-233B-49CC-8AA9-EC70A0D5C3D7Q38036202-1D64DCB7-D517-48B2-99C6-1845F1D8B9B7Q38073096-15008A8B-851A-4484-A89A-BC80E6EB682AQ38099612-25A80C24-0490-44FC-9061-C0CD1C0153F6Q38105081-25C5B2A7-424B-4974-A4E8-B72E21F582FFQ38148774-8F7EA919-55B0-40E3-9DC6-5E176776E4F6Q38174828-C8A411CB-B7EB-4A92-AAB7-D90F6B041E63Q38352462-495BFB79-1A0D-44A0-8483-EF9FD1BD325CQ38616461-DEFE3F53-27BD-414E-9024-422FC72960F3Q38657642-FC5738EB-670E-48FC-AE62-0923652FB7A0Q38673161-D4812A1F-7695-4949-93A8-90C83BE1629BQ38727470-6EBACE44-AC8A-464C-9FA1-7F99D4171D07Q38843235-F9F6999B-D517-465E-A2D6-8D25A31295A0Q39043404-3E4F9220-0A1A-4AF1-808D-B6FDA9435F77Q39250390-5FC5A5FB-A970-4E28-A274-3F766C653531Q39289930-CA116E51-927C-4EFD-8899-88385757259EQ39564433-4835053C-68DE-43B7-93E5-F80AEE7F4696Q39794478-9AE071D9-0714-40B7-8416-73B5CE1C57A6Q40140002-3AEEDF85-E687-4E4F-B7B1-25D5F6FB972DQ41275812-DFCCC667-E112-40AB-9B1B-A2DF9200ED0EQ41831989-39133F7E-547C-48F7-B281-F394E234664AQ42734547-BB5F5F04-FF4C-48E8-B990-20FAB8EEEC97
P2860
Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Vaccination with autologous tu ...... urable disease: a pilot study.
@en
Vaccination with autologous tu ...... urable disease: a pilot study.
@nl
type
label
Vaccination with autologous tu ...... urable disease: a pilot study.
@en
Vaccination with autologous tu ...... urable disease: a pilot study.
@nl
prefLabel
Vaccination with autologous tu ...... urable disease: a pilot study.
@en
Vaccination with autologous tu ...... urable disease: a pilot study.
@nl
P2093
P50
P1433
P1476
Vaccination with autologous tu ...... surable disease: a pilot study
@en
P2093
Alessandro M Gianni
Fernando Ravagnani
Michele Magni
Paola Baldassari
Paola Matteucci
P356
10.1182/BLOOD-2008-06-165654
P407
P50
P577
2008-09-22T00:00:00Z